Cite
HARVARD Citation
Lip, G. et al. (2016). Major bleeding risk among non‐valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real‐world" observational study in the United States. International journal of clinical practice. 70 (9), pp. 752-763. [Online].